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Abstract
Background: Malaria remains a burden in Sub-Saharan Countries. The strategy proposed by the World Health 
Organization (WHO) is to systematically compare the therapeutic efficacy of antimalarial drugs using as primary 
outcome for efficacy, a four-category ordered criterion. The objective of the present work was to analyze the treatment 
effects on this primary outcome taking into account both a center-effect and individual covariates. A three-arm, three-
centre trial of Amodiaquine (AQ), sulfadoxine-pyrimethamine (SP) and their combination (AQ + SP), conducted by 
OCEAC-IRD in 2003, in 538 children with uncomplicated Plasmodium falciparum malaria, is used as an illustration.
Methods: Analyses were based on ordinal regression methods, assuming an underlying continuous latent variable, 
using either the proportional odds (PO) or the proportional hazards (PH) models. Different algorithms, corresponding 
to both frequentist- and bayesian-approaches, were implemented using the freely available softwares R and Winbugs, 
respectively. The performances of the different methods were evaluated on a simulated data set, and then they were 
applied on the trial data set.
Results: Good coverage probability and type-1 error for the treatment effect were achieved. When the methods were 
applied on the trial data set, results highlighted a significance decrease of SP efficacy when compared to AQ (PO, odds 
ratio [OR] 0.14, 95% confidence interval [CI] 0.04-0.57; hazard ratio [HR] 0.605, 95% CI 0.42-0.82), and an equal 
effectiveness between AQ + SP and AQ (PO, odds ratio [OR] 1.70, 95% confidence interval [CI] 0.25-11.44; hazard ratio 
[HR] 1.40, 95% CI 0.88-2.18). The body temperature was significantly related to the responses. The patient weights were 
marginally associated to the clinical response.
Conclusion: The proposed analyses, based on usual statistical packages, appeared adapted to take into account the 
full information contained in the four categorical outcome in malaria trials, as defined by WHO, with the possibility of 
adjusting on individual and global covariates.
Background
Many clinical trials have a primary outcome which is
measured on a categorical scale. In these situations, the
outcome categories are often ordered, either by a direct
relationship to either a continuous measurement or a
clinical score through pre-defined cut-points, or by a nat-
ural interpretation by the physician of a health condition
or body reaction.
An overview and recent developments in the analysis of
ordered categorical data have been presented in [1-4].
More specific developments for analyzing ordinal data in
the context of meta-analysis of clinical trials have been
proposed initially for summary statistics [5,6], second-
arily extended to meta-analysis with individual patient's
data [7,8].
The main objective of this paper was to adapt and
implement the above-proposed methods in the specific
context of malaria. A more specific objective was to study
the effect of both different treatments and a set of covari-
ates on the primary outcome.
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In antimalarial trials, the WHO (World Health Organi-
zation) established a clinical study protocol [9,10] to
assess the efficacy of antimalarial drugs for uncompli-
cated malaria, in which the primary outcome is a four-
category outcome, i) ACPR (adequate clinical and para-
sitological response); ii) LPF (late parasitological failure);
iii) LCF (late clinical failure) and; iv) ETF (early treatment
failure). Patient status reflects the ordinal character of the
WHO criteria. Danger signs appearing on day 1, 2 or 3
with a persistent parasitaemia correspond to an ETF. The
presence of fever and parasitaemia between day 4 and day
14 without an ETF is considered as LCF, whereas the
presence of parasitaemia on day 14 without ETF and LCF
is a LPF . ACPR corresponds to the absence of parasite
regardless the body temperature on day 14 without being
classified as either ETF, or LCF or a LPF previously. This
suggests that there is an explicit order between the cate-
gories. A multi-centre randomized controlled trial of
three antimalarial drugs, amodiaquine (AQ), sulfadoxine-
pyrimethamine (SP) and their combination (AQ + SP),
which was conducted in 2003 by OCEAC-IRD in patients
with uncomplicated P. falciparum malaria from 3 health
centers in Cameroon, according to the WHO protocol
[9,10] will be used to illustrate the statistical approach.
Briefly, the 3 centers were selected as they were known
to be associated with different levels of transmission.
Affected children, 0-5 years old, were the target popula-
tion, according to the WHO recommendations for
assessing antimalarial drug efficacy. The primary out-
come of efficacy was the four category-variable: C1 =
ACPR, C2 = LPF, C3 = LCF, and C4 = ETF, the first cate-
gory being the best category and the last category being
the worst, in terms of health condition. Table 1 describes
the results for each arm of anti-malarial drug, in the three
centers. The majority of patient outcomes were assigned
in the first category, with very few treatment outcomes in
the other categories, corresponding to various degrees of
therapeutic failures. The protocol was approved by both
the Ministry of Public Health and the Ethical National
Committee. The person legally in charge of the children
gave an informed consent before inclusion in the study.
Study investigators were OCEAC field workers. A global
analysis of the data, based on the rate of ACPR can be
found in [11].
Methods
Statistical methods
The proportional odds model
The statistical approach is based on the proportional
odds model [12]. Consider the K = 3 centers. Each patient
had a response into one of the m = 4 categories, (C1, ..,
Cm), with ni patients in center i. Let   be the total
number of patients overall.
Denote Z the response and πijc, the probability that the
jth subject in study i had a response in category c; πijc =
Pr(Zij = c). Let also Qijc = Pr(Zij ≤ c) be the cumulative
probability of a response in category c or better, so that
Qijc = πij1 + ... + πijc and Qijm = 1; c = 1, ..., m-1. Hence c = m
corresponding to the worst outcome (here an ETF) is the
baseline level. The proportional odds model is defined by
where αc represents the cth intercept and ηij = γ1 x1ij +
...+  γp xpij, is a linear combination of explanatory vari-
ables. The model assumes 1) an increasing order for the
αc: α1 <α2 < ... <αm-1; 2) α0 = -∞ and αm = ∞.
The assumption of proportional odds signifies that the
ratio of the odds of the event Zij ≤ c for any pair of sets of
explanatory variables is independent of the category c.
The cumulative logit model (1) results from the existence
of a latent random variable with a logistic distribution,
the (αc, c = 0, ..., m) corresponding to the cut-off thresh-
olds for categorizing the latent variable into m classes.
Alternatives to the proportional odds model can be
developed based on different assumptions regarding the
latent variable, like a normal- or an extreme value distri-
bution associated with the probit or complementary log-
log links, respectively.
Fixed effect model The basic model extends the propor-
tional odds model (PO) proposed in [7] to a situation
with L treatments (L > 2). For the sake of simplicity, the
presentation will be restricted to the situation of L = 3
treatments corresponding to the real data set but the
extension to more than 3 treatments is straightforward.
Assuming that one particular treatment (here, AQ) was
selected as the reference treatment, the treatment covari-
ate is modeled using L-1 = 2 dummy variables T1 and T2,
where Tl (l = 1, L-1) yields 1 if subject received the treat-
ment l, and 0 otherwise (here, l = 1 corresponds to SP, l =
2 corresponds to AQ + SP)
where {j  = 1, ..., ni,} corresponds to the individuals
within each arm, {i = 1, .., K}, corresponds to the centers
and {c = 1, ..., m-1} to the categories. The parameter γ1
represents the log-odds ratio of efficacy associated to
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treatment 1 versus  the reference treatment, and γ2 the
log-odds ratio of efficacy associated to treatment 2 versus
the reference treatment.
The center effects are modeled by γ0i where γ01 = 0 for
identifiability constraint.
Testing the proportional odds assumptions It is worth
noting that model (2) assumes that, within each center
and for each outcome category c, (c = 1, .., m-1), there is a
common log-odds ratio, γ1 for treatment l versus the ref-
erence treatment. Similarly, model (2) assumes also that,
within each treatment group, and for each outcome cate-
gory c there is a common log-odds ratio, γ0i - γ0i, between
two centers i and i', independent of the outcome category.
Additional models were introduced to test the PO
assumption. Model (3) allows for testing a global PO
between treatments, without a center effect:
However, each treatment can have a different effect
according to the outcome category.
Assuming a global PO for T1, the model (4) allows for
testing PO between T2 and the reference treatment
where δhc = 1 if h = c and 0, otherwise.
Similarly, the model (5) assumes a global PO for T2, and
allows for testing PO between T1 and the reference treat-
ment (here AQ)
la g g ijc c 1 ij 2 ij =+ T + T 12 . (3)
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m
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Table 1: Counts of treatment response by category stratified in all centers and treatments.
C1 C2 C3 C4
Center Treatment ACPR LPF LCF ETF Total
A Q 6 2 0016 3
[98.4]** [0] [0] [1.6] [100.0]
1 S P 5 3 2066 1
[86.8] [3.27] [0] [9.8] [100.0]
A Q + S P 5 9 0005 9
[100.0] [0] [0] [0] [100.0]
A Q 5 2 2005 4
[96.3] [3.7] [0] [0] [100.0]
2 S P 4 8 0235 3
[90.56] [0] [3.7] [5.26] [100.0]
A Q + S P 5 5 1005 6
[98.2] [1.8] [0] [0] [100.0]
A Q 5 7 0015 8
[98.2] [0] [0] [1.7] [100.0]
3 S P 5 2 2035 7
[91.2] [3.5] [0] [5.26] [100.0]
A Q + S P 5 8 0005 8
[100.0] [0] [0] [0] [100.0]
Total 496 7 2 14 519
[95.5] [1.3] [0.38] [2.7] [100.0]
** Row percentage. The categories C1, C2, C3, and C4 represent ACPR, LPF, LCF and ETF, respectively.Whegang et al. BMC Medical Research Methodology 2010, 10:58
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Mixed effects model Discarding a center effect, and still
assuming proportional odds between treatments, 2 ran-
dom effects were added to the treatment variables.
where: β1i = γ1 + δ1i and β2i = γ2 + δ2i. Both δ1i and δ2i are
normally distributed random effects with expected value
0 and variance  ,   respectively.
By grouping separately the fixed and the random-
effects, the model can be rewritten as follows:
where ,  where  G', the transposed
matrix of G, needs to be estimated from the data.
Estimation methods
The parameters of the fixed effects models were esti-
mated using three different methods, i.e. maximum likeli-
hood (ML), iterative generalized least squares (IGLS) and
generalized estimating equations (GEE) [7]. In the IGLS
and GEE methods, the ordinal response was considered
as a set of correlated binary responses. Thus the propor-
tional odds model is viewed as a member of the multivar-
iate generalized linear models [13].
All these methods were implemented under the free
Statistical Software R http://cran.r-project.org/. The vari-
ous codes for the ML, GEE and IGLS methods are in the
additional file 1. Models (3), (4) and (5) were imple-
mented for the test of the proportional odds assumption
between centers and treatments. The parameters of the
random effects model were estimated using a Bayesian
approach for hierarchical models. In the Bayesian para-
digm, prior distributions for all unknown parameters θ
need to be specified. The intercept αc were given non-
informative N(0,104) priors. Parameters β1i and β2i were
assumed to be from N(γ1, σ1
2) and N(γ2, σ2
2) respectively.
We gave γ1, γ2 non-informative N(0,10-6). The difficulty in
the Bayesian paradigm is the choice of the a priori distri-
bution for the inverse of the variances σ1
2 and σ2
2. Several
forms of the a priori are available. We chose an a priori of
the form Gamma(0.5η, 0.5ηζ2), where η and ζ2 are either
arbitrary chosen or calibrated from the data. Here we
chose  η  = 2. The initial estimated values of ζ2 (0,007,
0,001) were obtained from our data, by adjusting a gener-
alized linear mixed model. So 1/σ1
2 and 1/σ2
2 were given
Gamma(1,0.007) and Gamma(1,0.001), respectively. All
the Bayesian analyses were performed using 3 chains of
50000 samples, out of which the first 25000 were
removed to allow for convergence. Thus, each posterior
statistic was based on 75000 samples. Finally the 95%
credibility interval was obtained for each statistic.
Simulations
To assess the performance of the fixed effect methods, we
carried out analyses on simulated data based on model
(6). The aim was to compare the methods when the treat-
ment covariate was taken into consideration and random
effects were introduced to account for center variability.
We generated a data set of 3 centers, each containing 100
patients, comparing 3 treatments A, B, C, with equal size.
We supposed that the treatment effects were the same in
the 3 centers, and were set to be γ1 = -1 for B comparing
to A and, γ2 = 1 for C comparing to A, respectively. Initial
values for αc were α01 = -2, α02 = -1, α03 = 0. The initial
value of the matrix G' was a diagonal matrix with diago-
nal elements σ1 = 0.01 and σ1 = 0.02, corresponding to the
between center deviation.
The choice of the treatment initial values was guided by
preliminary results from real data. The choice for the cut-
point values was derived from [14].
Cumulative probabilities Qijc were then obtained using
model (6). For a subject j in study i, with vector of cumu-
lative probabilities (0, Qij1, Qij2, Qij3, 1), the simulated out-
come was generated using the quartile range category, to
which an uniformly (0,1) distributed random value
belonged. To check that the conclusions were not sensi-
tive to the choice of the starting values, we repeated the
simulations, for each method, with different initial values.
An example of the simulated data set can be found in
additional file 2.
For each method, bias and confidence levels were esti-
mated through N 1000 = replications. For each estimation
method, the treatment effect was assessed using the cal-
culated coverage probability and the type I error.
In the Bayesian analysis, model (6) was implemented
using the Bayesian Software WinBUGS. A program is
provided in the additional file 3, showing how model (6)
can be written in BUGS language.
Results
Simulated data set
Results are summarized in Table 2. The ML-, IGLS- and
GEE- methods yielded similar results. For the detection
bias, the ML estimate appeared less biased than the two
other methods. Considering their coverage probabilities
(CP = 1- β), all the three approaches appeared to be able
to detect a significant treatment effect with a given type I
error α.
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Analysis of the Multi-centre trial
Results based on treatment and center effect only
Among the n = 538 patients from the three centers, 19
patients were lost to follow-up by day 14 and hence could
not contribute to the analyses.
Results from the randomized trial are displayed in
Table 3 with a general view of the fixed and the Bayesian
approach. All the methods showed a significant decrease
of the SP effect as compared with AQ. The SP treatment
appeared less efficacious than AQ, by all the three fixed
methods (ML: OR = e-1.93 = 0.14; 95% CI 0.04-0.50; IGLS:
OR = e-1.77 = 0.17; 95% CI 0.04-0.58; GEE: OR = e-1.80 =
0.16; 95% CI 0.04-0.57). The combination AQ-SP was not
significantly different by the three approaches. The addi-
tional file 4 shows how practically these fixed estimates
can be obtained with an example of the different output
given in additional file 5.
The between center variability was   = 0.023 (95%
credibility interval 0.001-0.107) for the SP/AQ treatment,
and   = 0.020 (95% credibility interval 0.0001-0.024) for
the AS+SP/AQ treatment. The assumption of propor-
tional odds between treatments and centers was tested
using the ML method by comparing the change in devi-
ance of the various models (T able 4) to the chi-squared
χ1-α
2 (2 df) which equals 5.99. The results indicate that the
assumption was satisfactory.
Results after covariates adjustment
Covariates known at the time of inclusion were the para-
sitaemia, the type of treatment, the gender, the patient's
age, the bodyweight (kg), a previous treatment before the
study enrollment, the haematocrit and the baseline body
temperature. The patient's bodyweight was log-trans-
formed; the initial parasitaemia counts were transformed
to normality using a Box-Cox transformation (estimated
power = 0.1028, p-value = 0.0056). The baseline haemat-
ocrit was categorized into two classes, below (A) and
above (B) 25%. The patient's age was also categorized into
3 categories: i) less than 1 year old (A); ii) between 2 and 4
years old (B); iii) more than 5 years old (C).
First, a univariate analysis including each covariate of
interest, in addition to the treatment covariates and the
s
∧
1
2
s
∧
2
2
Table 2: Simulation results.
Methods Bias (*) 1-β (α)
Parameters Real values ML IGLS GEE ML IGLS GEE ML IGLS GEE
Cut-points
α1 -2 -2.149 -2.149 -2.143 0.014 0.007 0.0137
(0.236) (0.237) (0.237) (7.34) (1.98) (6.76)
α1 -1 -1.053 -1.053 -1.040 0.012 0.002 0.0136
(0.214) (0.211) (0.217) (7.35) (1.69) (7.91)
α3 0 -0.106 -0.106 -0.103 0.0055 -0.0043 0.0025
(0.206) (0.204) (0.207) (3.57) (1.6) (1.56)
Treatment effects
γ01 -1 -1.016 -1.016 -0.941 0.0077 0.0195 0.0098 0.938 0.948 0.94
(0.242) (0.240) (0.248) (3.22) (2.42) (3.75) (0.014) (0.013) (0.015)
γ02 1 1.078 1.078 1.082 -0.005 -0.0043 -0.0111 0.943 0.943 0.945
(0.214) (0.215) (0.217) (2.27) (2.20) (5.05) (0.003) (0.001) (0.001)
Center effect
C1 0.218 0.218 0.168
(0.224) (0.224) (0.228)
C2 -0.014 -0.014 0.013
(0.228) (0.226) (0.230)
Fixed models. Column 2 corresponds to the real values used for simulating data.
Columns 3-5 correspond to the mean estimates according to different methods with the corresponding standard error estimates in brackets; 
columns 6-8 correspond to the corresponding absolute and relative biases (*); columns 9-11 corresponds to the coverage probability and, in 
brackets, the type I error for the treatment effect only.Whegang et al. BMC Medical Research Methodology 2010, 10:58
http://www.biomedcentral.com/1471-2288/10/58
Page 6 of 10
centre covariate was performed. Then only covariates
with a p-value under 10% were selected for a multivariate
analysis. Only the baseline temperature reached a statisti-
cal significance (Table 5). Multivariate analysis did not
change the magnitude of the treatment effects.
As all the estimated intercept values were strictly posi-
tive, the assumption of a logistic distribution for the
latent variable could be replaced with an extreme value
distribution, using a model with a complementary log-log
(cloglog) link function [2]. In Table 6, the corresponding
results show that the intercept value-estimates were
reduced as compared to the corresponding ones using the
logistic distribution. However, the treatment parameter
estimates did not change although the interpretation is
not strictly the same. Indeed, as pointed out by Agresti
[2], trying a complementary log-log link function is
Table 3: summary of parameter estimates using both the fixed effect models and the bayesian approach in the anti-
malarial trial.
Fixed Approach Bayesian Approach
ML IGLS GEE WinBUGS
Category associated cut-points
α1 3.850 3.880 3.665 3.915
(0.63) (0.64) (0.63) (0.50)
α2 4.237 3.880 4.060 4.359
(0.65) (0.64) (0.64) (0.51)
α3 4.380 4.237 4.203 4.572
(0.67) (0.66) (0.65) (0.52)
Treatment (Reference: AQ)
SP/AQ -1.938* -1.776* -1.800 * -1.760*
(0.63) (0.64) (0.63) (0.57)
AQ+SP/AQ 0.537 1.797 2.081 1.601
(0.97) (1.53) (1.72) (1.09)
Center (Reference: Yaoundé)
Bertoua/Yaoundé 0.196 0.100 0.242
(0.51) (0.55) (0.55)
Gardoua/Yaoundé 0.460 0.458 0.475
(0.53) (0.59) (0.57)
*Treatment effect estimates in presence of a center effect. For each outcome category, the SP treatment was less efficacious than the AQ 
treatment.
Table 4: Test of the proportional odds between centers and treatments on the anti-malarial trial data set.
Tests Model comparisons ML results Change in deviance
Proportional odds 5 vs. 3 0.10 (2 d.f.)
between SP and AQ p > 0.95
Proportional odds 4 vs. 3 2.24 (2 d.f.)
between AQ-SP and AQ p > 0.32
Proportional odds 2 vs. 3 0.2 (2 d.f.)
between centers p > 0.90Whegang et al. BMC Medical Research Methodology 2010, 10:58
http://www.biomedcentral.com/1471-2288/10/58
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equivalent to fitting a proportional hazards model. Hence
regarding the comparison of the SP treatment to the ref-
erence treatment AQ, the parameter e-0.502 = 0.605 (95%
CI 0.44-0.82) is interpreted as a hazards ratio which is
assumed constant regardless the response category. It
suggests that the proportion of patients having positive
response was more decreased with SP than with AQ.
Between AQSP and AQ, the hazards ratio was 1.40 (95%
CI 0.88-2.18), suggesting that there was no difference in
efficacy.
Discussion
The present work applied methods, initially presented in
the context of a meta-analysis comparing 2 treatment
effects with a categorical outcome, to the analysis of
multi-center-antimalarial trials, comparing 3 treatments,
with a 4-categorical primary outcome, using individual
patient data. All the methods were implemented using
free available softwares. Their performances were
assessed using simulated data sets. Both a frequentist and
Bayesian approaches were implemented. In the simula-
tion settings, we considered a general case of a mixed
effects model. The ML method was faster than the IGLS
and GEE methods. All the methods produced minimal
biases. Another R function can be used like lrm (Hmisc
library using the library Design) which is more restricted
at present in the choice of the link functions.
Our results from the multi-centre trial showed a signif-
icant decrease in efficacy in the sulfadoxine-
pyrimethamine-arm as compared with the amodiaquine-
arm. This means that there was less ACPR and more fail-
ures with SP. No significant difference was observed
between amodiaquine and the combination AQ + SP.
Similar results hold for both the frequentist and Bayesian
approaches. The proportional odds assumption between
treatments was not rejected. The proposed model can be
a useful way when dealing with a small number of centers
with more than 2 treatments.
Regarding the dependence between the outcome and
the explanatory variables, a recent study [15] reported
patient's age as a significant factor associated with anti-
malarial treatment failure, more specifically with
artemisinin derivatives and quinine. Indeed, the study
showed that children less than 5 years old had a signifi-
Table 5: Effect of individual covariates on the ordinal outcome.
Univariate Multivariate
E s tS DZ - v a l u e E s tS DZ - v a l u e
Global covariates
- Treatment (Reference: AQ)
SP/AQ -1.776 0.633 2.805 -1.638 0.566 2.893
AQ+SP/AQ 1.797 1.533 1.172 1.418 1.128 1.257
- Center (Reference: Yaoundé)
Bert/Ydé 0.100 0.550 0.181
Gar/Ydé 0.458 0.589 0.777
Individual covariates
- Baseline temperature* -0.577 0.264 2.18 -0.614 0.266 2.308**
- Fever before inclusion -0.003 0.070 0.05
- Parasitemia -0.072 0.071 1.02
- Hematocrit Day 0 0.341 0.518 0.74
- Automedication Y/N 0.014 0.524 0.03
- Age B/A 0.391 0.511 0.77
- Age C/A 0.989 0.728 1.35
- Age (months) 0.010 0.012 0.87
- Gender M = 1/F = 0 0.279 0.468 0.60
- Bodyweights* 1.373 0.716 1.91 0.113 0.06 1.91
Univariate analysis of the individual covariate performed in presence of the treatment covariate.
*Only variable with a p-value below 10% were retained for the multivariate analysis. *: p < 0.05Whegang et al. BMC Medical Research Methodology 2010, 10:58
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cant risk of treatment failure as compared with children
more than 5 years. In our analysis, no significant age
effect was found, but our data concerned mostly children
less than 5 years. Covariates, like haematocrit, gender,
auto-medication before study enrollment, were not sig-
nificant. In contrast, the baseline temperature was signifi-
cantly associated with the outcome, showing that patients
with a low temperature at inclusion were more likely to
have a good treatment response. For the SP treatment,
the decrease could be related to a gene mutation, respon-
sible for a resistance towards SP [16-18]. The SP resis-
tance was also confirmed in a recent study in South
Africa [19]. The emergence of resistance led to the use of
Artemisinin-based Combination Therapies (ACTs)
which play an important role in the reduction of malaria
transmission [20]. Thus, ACTs are widely used as first-
line treatment of malaria in Africa [21-28].
The present work presented some statistical methods
to handle the WHO criteria globally. They appear
adapted for assessing antimalarial treatment in clinical
trials, or in other studies with an ordinal outcome. It con-
trasts with previous methods [15], which reduced the
outcome into a binary variable, for instance ACPR versus
non ACPR. Only 3.5% were missing data. By eliminating
drop-out or excluded patients in the final analysis, we
assumed that they were missing completely at random
(MCAR). Incorporating these into the analysis would
require an imputation of the missing category. For such
imputation, wide-range methods have been studied [29],
but remain a topic to study in the case of malaria.
Other study designs are presently available in which
patients have repeated standardized visits during their
follow-up. Thus repeated categorical responses are avail-
able for each subject. All methods used in the case of a
Table 6: Model fitting with the complementary log-log link function and results comparisons.
ML ML ML ML
Logit Cloglog Logit Cloglog
Category cut-points
α1 3.850 1.297 25.980 8.201
(0.63) (0.16) (10.65) (3.54)
α2 4.237 1.431 26.39 8.346
(0.65) (0.17) (10.66) (3.54)
α3 4.380 1.478 26.540 8.401
(0.6¬¬6) (0.17) (10.66) (3.54)
Treatment (Reference AQ)
SP/AQ -1.938 -0.524 -1.638 -0.502
(0.63) (0.16) (0.57) (0.16)
AQ+SP/AQ 0.537 0.348 1.416 0.329
(0.97) (0.24) (1.13) (0.23)
Center (Reference Yaoundé)
Bert/Ydé 0.196 -0.016
(0.51) (0.17)
Gar/Ydé 0.460 0.123
(0.53) (0.18)
Individual Covariate
Baseline temperature -0.604 0.188
(0.27) (0.09)
Bodyweights 0.113 0.037
(0.06) (0.02)
Parameter estimates with the corresponding standard error estimates on the following line.Whegang et al. BMC Medical Research Methodology 2010, 10:58
http://www.biomedcentral.com/1471-2288/10/58
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single categorical response, can however, be extended to
repeated categorical responses [30].
Conclusion
The approach of modeling the WHO criterion as an ordi-
nal criterion is innovative in the sense that, it gives a gain
of information and precision on the estimate of the treat-
ment effect using a global analysis of the four-category
outcome instead of either comparing the rate of ACPR
only, without being able to differentiate treatments when
they present an identical percentages in the ACPR cate-
gory but, different repartitions in the remaining three
other categories, or repeating a similar binary analysis for
each category, then exposing to the increase of the type-1
error. This analysis could help in avoiding a conclusion on
an equal treatment effect whereas there is not or, vice-
v e r s a .  I n  a d d i t i o n ,  t h i s  a p p r o a c h  i s  a b l e  t o  t a k e  i n t o
account individual's covariates to improve the prediction
of efficacy.
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